SAN DIEGO, Sept. 17, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the “Convertible Notes”). The offering size was increased…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
